Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p75
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 75/191)
Character Range: 10358749–10369274

- Streamlined Authority Code 6882
                                                                                                                                                                                                                               Commencement of a short-term (9 weeks) course of treatment
                                                                                                                                                                                                                               The treatment must be as an aid to achieving abstinence from smoking; AND
                                                                                                                                                                                                                               The treatment must be the sole PBS-subsidised therapy for this condition; AND
                                                                                                                                                                                                                               Patient must have indicated they are ready to cease smoking; AND
                                                                                                                                                                                                                               Patient must not receive more than 9 weeks of PBS-subsidised treatment with this drug per 12-month period; AND
                                                                                                                                                                                                                               Patient must be undergoing concurrent counselling for smoking cessation through a comprehensive support and counselling program or is about to enter such a program at the time PBS-subsidised treatment is initiated.
                                                                                                                                                                                                                               Details of the support and counselling program must be documented in the patient's medical records at the time treatment is initiated.
C6885               P6885          CN6885           Varenicline                                                                                                                                                                Nicotine dependence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 6885
                                                                                                                                                                                                                               Completion of a short-term (24 weeks) course of treatment
                                                                                                                                                                                                                               The treatment must be as an aid to achieving abstinence from smoking; AND
                                                                                                                                                                                                                               The treatment must be the sole PBS-subsidised therapy for this condition; AND
                                                                                                                                                                                                                               Patient must have previously received PBS-subsidised treatment with this drug during this current course of treatment; AND
                                                                                                                                                                                                                               Patient must have ceased smoking in the process of completing an initial 12-weeks or ceased smoking following an initial 12-weeks of PBS-subsidised treatment with this drug in the current course of treatment; AND
                                                                                                                                                                                                                               Patient must be undergoing concurrent counselling for smoking cessation through a comprehensive support and counselling program.
C6886               P6886          CN6886           Fosaprepitant                                                                                                                                                              Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 6886
                                                                                                                                                                                                                               The condition must be associated with cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone; AND
                                                                                                                                                                                                                               Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents:
                                                                                                                                                                                                                                altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin.
                                                                                                                                                                                                                               No more than 1 vial of fosaprepitant 150 mg injection will be authorised per cycle of cytotoxic chemotherapy.
C6887               P6887          CN6887           Fosaprepitant                                                                                                                                                              Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 6887
                                                                                                                                                                                                                               The condition must be associated with moderately emetogenic cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone on day 1 of a chemotherapy cycle; AND
                                                                                                                                                                                                                               Patient must have had a prior episode of chemotherapy induced nausea or vomiting; AND
                                                                                                                                                                                                                               Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following intravenous chemotherapy agents:
                                                                                                                                                                                                                                arsenic trioxide; azacitidine; cyclophosphamide at